Ascendis Pharma A/S
NASDAQ · ASND·Hellerup, Denmark·Large-cap·Approved
Commercial-stage rare-disease endocrinology biotech leveraging the proprietary TransCon prodrug platform to deliver transient-linker conjugates of established parent drugs. Markets Skytrofa (lonapegsomatropin) for pediatric growth hormone deficiency and Yorvipath (palopegteriparatide) for adult hypoparathyroidism, with TransCon CNP (navepegritide) advancing in achondroplasia and an oncology pipeline anchored by TransCon TLR7/8 Agonist.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Ascendis Pharma Corporate Presentation | Corporate overview | January 13, 2026 | 30 |